Web Results

Amgen Inc. et al v. Sanofi et al - Law360


Parties, docket activity and news coverage of federal case Amgen Inc. et al v. Sanofi et al, case number 1:14-cv-01317, from Delaware Court.

Aventis' Clomid Defeats Claims of Inadequate Warnings Based on ...


Mar 23, 2016 ... Plaintiff Victoria Cerveny allegedly took Clomid in September and October 1992. Shortly ... The case name is Cerveny et al v. Sanofi et al.

Amgen Inc. v. Sanofi et al - RPX Search - RPX Corporation


Amgen Inc. v. Sanofi et al. 1:14-cv-01393; Filed: 11/11/2014; Closed: 01/05/2017; Latest Docket Entry: 01/05/2017; PACER. Thank you for your request. We will ...

Current Status: Site-Specific Antibody Drug ... - Semantic Scholar


Mar 22, 2016 ... recently, Zhang et al. introduced a different approach to reduce the heterogeneity in ... In 2014, Sanofi-Genzyme published a combinatorial .... Slamon DJ, Leyland- Jones B, Shak S, Fuchs H, Paton V,. Bajamonde A, et al. ... Hamblett KJ, Senter PD, Chace DF, Sun MM, Lenox J, Cerveny. CG, et al. Effects of ...

Current Status: Site-Specific Antibody Drug Conjugates - NCBI - NIH


Mar 22, 2016 ... Very recently, Zhang et al. introduced a different approach to reduce the ... In 2014, Sanofi-Genzyme published a combinatorial approach of ...

Safety and activity of the anti-CD79B antibody–drug conjugate ...


Apr 26, 2015 ... Vss=volume of distribution at steady state. tmax=time to reach the maximum concentration. ..... CD19-targeted maytansinoid antibody–drug conjugate SAR3419 (Sanofi, Paris, .... 9Francisco, JA, Cerveny, CG, Meyer, DL et al.

Medical Countermeasures for Radiation Exposure and Related I ...


... dose rate, the quality of radiation, and the time and extent of bodily exposure (;; ). ..... 2 h after irradiation had lower efficacy than a pre-irradiation injection (i.e., 12 % vs. ..... (sargramostim) is 5–10 μg kg<sup>−1</sup> d<sup>−1</sup> sc or (200–400 μg m<sup>−2</sup> d<sup>−1</sup>) (;).

Antibody Drug Conjugates as Cancer Therapeutics - MDPI.com


Feb 27, 2013 ... CD19. Hz IgG1 SPDB. Maytansine DM4 Phase II NHL sanofi. BT062. CD138 ..... Doronina, S.O.; Toki, B.E.; Torgov, M.Y.; Mendelsohn, B.A.; Cerveny, C.G.; Chace, D.F.;. DeBlanc, R.L.; Gearing, R.P.; Bovee, T.D.; Siegall, C.B.; et al. .... Kovtun, Y.V.; Goldmacher, V.S. Cell killing by antibody-drug conjugates.

Fighting bacterial infections—Future treatment options - ReAct

www.reactgroup.org/uploads/react/resources/105/Fighting bacterial infections - Future treatment options.pdf

et al., 2009) and lipohexapeptides (Zhang and Falla, 2010) are all classes .... for quorum sensing in E. coli and V. cholerae were also identified .... 2010) and Vibrio vulnificus (Cerveny et al., 2002). .... KaloBios Pharmaceuticals/Sanofi Pasteur.

Therapeutic options in relapsed or refractory peripheral T-cell ...


[6]; D.D. Weisenburger, K.J. Savage, N.L. Harris, et al. .... [22]; P.L. Zinzani, F. Venturini, V. Stefoni, et al. .... [42]; J.A. Francisco, C.G. Cerveny, D.L. Meyer, et al.